What's in Parc de Salut Mar's pipeline?

Parc de Salut Mar has 16 drugs in our index: 5 marketed, 0 filed, 2 in Phase 3, 3 in Phase 2, 5 in Phase 1.

Which companies overlap with Parc de Salut Mar's portfolio?

Top competitors by shared drug class: AIDS Malignancy Consortium, ANI Pharmaceuticals, AbbVie, Acrotech Biopharma Inc., Allergan.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/parc-de-salut-mar.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Parc de Salut Mar — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Parc de Salut Mar pipeline: 5 marketed, 0 filed, 2 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 2 Phase 3 3 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Inhaled Corticosteroids (ICs)	Inhaled Corticosteroids (ICs)	marketed	Corticosteroid	Glucocorticoid receptor	Respiratory/Pulmonology
Oral strogen	Oral strogen	marketed
Transdermal strogen	Transdermal strogen	marketed	Hormone replacement therapy (HRT) / Estrogen replacement	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)	Endocrinology / Women's Health
Polyethylene glycol + ascorbate	Polyethylene glycol + ascorbate	marketed	Osmotic laxative bowel preparation agent		Gastroenterology
Sodium picosulfate + magnesium citrate	Sodium picosulfate + magnesium citrate	marketed	Stimulant laxative + osmotic laxative combination		Gastroenterology
PEG-ascorbate 2L	PEG-ascorbate 2L	phase 3	Antioxidant/Vitamin derivative	Ascorbate receptor (SVCT1/SVCT2) and general oxidative stress pathways	Oncology
PEG 4L	PEG 4L	phase 3

Therapeutic area mix

Gastroenterology · 2
Endocrinology / Women's Health · 1
Oncology · 1
Other · 1
Respiratory/Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AIDS Malignancy Consortium · 1 shared drug class
ANI Pharmaceuticals · 1 shared drug class
AbbVie · 1 shared drug class
Acrotech Biopharma Inc. · 1 shared drug class
Allergan · 1 shared drug class
Aramis Biosciences, Inc. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
· 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Parc de Salut Mar:

Cite this brief

Drug Landscape (2026). Parc de Salut Mar — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/parc-de-salut-mar. Accessed 2026-05-16.